Filed Pursuant to Rule 424(b)(5)
Registration File No. 333-249218
Prospectus Supplement
(To prospectus dated October 14, 2020)
Up to $4,027,000 Shares of Common Stock
On December 20, 2016, we entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), relating to shares of our common stock, $0.01 par value per share, offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the Sales Agreement, we may offer and sell shares of common stock having a maximum aggregate sales price of up to $5,000,000 from time to time through Wainwright as sales manager. On October 1, 2020, we filed a new registration statement on Form S-3 (File No. 333-249218) of which this prospectus supplement forms a part, which registration statement became effective on October 14, 2020. On December 11, 2020, we entered into an amendment to the Sales Agreement (“Amendment No. 3”) with Wainwright to, among other things, reflect the new registration statement and to extend the term of the Sales Agreement.
Amendment No. 3 also modifies the maximum amount that may be sold under the Sales Agreement. Under the terms of the amended Sales Agreement, the Company may sell a number of shares of common stock equal to the lesser of (i) the number or dollar amount of shares reflected in this prospectus supplement, (ii) the number of authorized shares of the Company, less the number of shares issuable upon exercise of existing derivative securities or otherwise reserved by the Company for future issuance, and (iii) the maximum amount allowable under the registration statement, including any limit imposed by General Instruction I.B.6 of Form S-3. Although the Sales Agreement no longer specifies a limit of $5,000,000, the Company’s Board of Directors has to date authorized only this amount for issuance under the Sales Agreement. As of the date of this prospectus supplement, we have sold 1,881,839 shares of common stock under the Sales Agreement for gross proceeds of $973,000, which sales were made under two prior registration statements (File No. 333-199026 and File No. 333-220461). Accordingly, we are filing this prospectus supplement to offer and sell a number of shares of common stock having a maximum aggregate sales price of $4,027,000.
Our common stock is listed on the NYSE American (“NYSE American”) under the symbol “AUMN” and on the Toronto Stock Exchange (“TSX”) under the symbol “AUMN”. On December 10, 2020, the closing price for our common stock on the NYSE American was $0.60 and on the TSX was Cdn$0.76.
As of December 10, 2020, the aggregate market value of our outstanding common stock held by non-affiliates was $71,054,238 based on 154,012,652 shares of outstanding common stock, of which 112,784,505 shares were held by non-affiliates, and a per share price of $0.63 based on the closing price of our common stock on December 8, 2020. During the prior twelve-calendar-month period that ends on, and includes, the date of this prospectus supplement, and excluding this offering, we offered securities with an aggregate market value of approximately $18,338,500 pursuant to General Instruction I.B.6. of Form S-3.
Sales of shares of our common stock, if any, may be made by any method permitted by law deemed to be “at the market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended, or the Securities Act, including without limitation sales made directly on or through the NYSE American or on any other existing United States trading market for our common stock or through a market maker or any other method permitted by law, including but not limited to, negotiated transactions. If we and Wainwright agree on any method of distribution other than sales of shares of our common stock onto the NYSE American or another existing trading market in the United States at market prices, we will file a further prospectus supplement providing the information about such offering as required by Rule 424(b) under the Securities Act. Wainwright will use commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us, consistent with their normal trading and sales practices, on mutually agreed terms between Wainwright and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.
Wainwright will be entitled to compensation at a commission rate of 2.0% of the gross sales price of all shares sold under the Sales Agreement. In connection with the sale of shares of common stock on our behalf, Wainwright is an “underwriter” within the meaning of the Securities Act, and the compensation of Wainwright may be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to Wainwright against certain liabilities, including liabilities under the Securities Act.
This prospectus supplement should be read in conjunction with and may not be delivered or utilized without the base prospectus dated October 14, 2020.
Investing in our common stock involves significant risks. Before buying shares of our common stock, you should carefully consider the risks described under “Risk Factors” beginning on page S-7 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
No shares of common stock distributed under this prospectus supplement will be offered or sold in Canada, including through the TSX or any other trading market in Canada. See “Plan of Distribution” on page S-21 of this prospectus supplement and “Restrictions on Resale to Residents of Canada” on page S-22 of this prospectus supplement. H.C. Wainwright & Co.
The date of this prospectus supplement is December 11, 2020